Renato Brito Baleeiro, Senior Scientist Project Lead at VacV Biotherapeutics, shared a post on LinkedIn:

“Armoured CAR T-cells engineered to withstand the tumour immunosuppressive micro-environment of solid tumours. Researchers reported a groundbreaking advancement in Chimeric antigen receptors (CAR) T-cell therapy targeting ROR1-positive tumours.

By developing a novel ROR1-CAR with a fully human single-chain variable fragment (scFv9) targeting domain and fortifying it with a dominant-negative form of the TRFβRII (TGFβRIIDN) armor against the suppressive tumour micro-environment, remarkable results were observed.

The novel Chimeric antigen receptors (CAR) T-cells exhibited superior functionality and tumour-clearing ability compared to the previous CAR, notably achieving complete remission in solid ovarian tumours in mice.

Moreover, the armored CAR demonstrated resilience against TGFβ-mediated inhibition, crucial for combating the immunosuppressive micro-environment found in solid cancers.

These findings present a promising avenue for enhanced CAR T-cell efficacy and potential clinical application.

The link to the original article. If you found this post valuable, give it a like and share it with your network!
Be at the forefront of cancer immunotherapy breakthroughs! Subscribe for FREE to my weekly Newsletter for a dose of knowledge and the latest advancements.”

Source: Renato Brito Baleeiro/LinkedIn